PerkinElmer to Acquire BioLegend in $5.25B Life Sciences Deal - IDEX Health & ScienceIDEX Health & Science


    The views, information, or opinions expressed in the Industry News RSS feed belong solely to the author and do not necessarily represent those of IDEX Health & Science and its employees.

    PerkinElmer to Acquire BioLegend in $5.25B Life Sciences Deal

    Article obtained from Photonics RSS Feed.

    PerkinElmer (PE) will make the largest transaction in its history. The company has entered into an agreement to acquire BioLegend, a global provider of life science antibodies and reagents, in a deal worth approximately $5.25 billion.

    The deal is expected to close in the third quarter of this year. The combined company will generate immediate revenue synergies that are expected to reach $100 million annually by the fifth year following the closing. No significant cost synergies are planned, a press release stated.

    BioLegend provides antibodies and reagents to academic and biopharmaceutical customers in cytometry, proteogenomics, multiplex assays, recombinant proteins, and other areas. Upon joining PE, BioLegend will expand…

    Jul, 26 2021 |

    IDEX Health & Science is the global authority in fluidics and optics, bringing to life advanced optofluidic technologies with our products, people, and engineering expertise. Intelligent solutions for life.